mobile nav toggler

investors

Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases. Our mission is to in-license, transform and develop clinical-stage, or nearly clinical-stage, therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune and inflammatory diseases.

recent releases
Aug 13, 2018

Recent Corporate Highlights: Closed initial public offering of common stock on July 19, 2018, generating $63.9 million in gross proceeds Expanded pipeline with two additional clinical-stage assets...

Jul 31, 2018

Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the appointment of Mark Rigby, MD,...

Jul 19, 2018

Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the closing of its initial public...

View All Releases >

current stock price
NASDAQPRVB
NASDAQPRVB

investor relations contact

For more information contact Joshua Drumm, Ph.D., Tiberend Strategic Advisors, Inc.
212.375.2664 

email Joshua

Sign Up For Email Alerts